Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 Jan;87(1):111–116. doi: 10.1111/j.1365-2249.1992.tb06422.x

Enhancement of the lytic activity of cloned human CD8 tumour-infiltrating lymphocytes by bispecific monoclonal antibodies.

A Gorter 1, K M Krüse 1, P I Schrier 1, G J Fleuren 1, R J van de Griend 1
PMCID: PMC1554219  PMID: 1531120

Abstract

We have isolated tumour-infiltrating lymphocytes (TIL) clones from a patient with renal cell cancer. The cloning frequency and the effector function were measured. No difference in cloning frequency (r2 = 0.97, frequency = 1:13) was observed between TIL expanded with allogeneic versus autologous feeder cells. Sixty-four clones expanded with autologous feeder cells and 37 clones expanded with allogeneic feeder cells were assayed for cytolytic activity on an autologous primary renal cell carcinoma (RCC) culture, an allogeneic RCC line, and on the K562 and Daudi cell lines. Most of these clones were also phenotyped. Although TIL clones expressing cytotoxic activity for RCC lines could be generated with both feeder cell preparations, none of the clones tested showed specificity for cells from autologous primary RCC cultures. However, in the presence of relevant bispecific MoAbs (alpha OC/TR) all CD8+ TIL clones tested could be induced to lyse autologous RCC cultures. Furthermore, the cytolytic activity of all CD8+ clones tested against allogeneic RCC lines could be induced or further enhanced by alpha OC/TR or CD3/G250 bispecific MoAbs. In contrast, none of the CD4+ clones tested showed lytic activity. Quantitatively the cytotoxic response in the presence of alpha OC/TR or CD3/G250 of CD8+ TIL clones against G250+ and MOv18+ cell lines appears to be associated with the level of antigen expression on the target cells. Our results suggest that: (i) expansion of TIL with allogeneic or autologous feeder cells does not effect the lytic profile of the clones; (ii) the use of bispecific MoAbs may overcome a lack of specificity of cytotoxic T lymphocytes.

Full text

PDF
111

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J., Rayman P., Edinger M., Connelly R., Tubbs R., Bukowski R., Pontes E., Finke J. TIL from renal-cell carcinoma: restimulation with tumor influences proliferation and cytolytic activity. Int J Cancer. 1990 Jan 15;45(1):119–124. doi: 10.1002/ijc.2910450121. [DOI] [PubMed] [Google Scholar]
  2. Belldegrun A., Muul L. M., Rosenberg S. A. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res. 1988 Jan 1;48(1):206–214. [PubMed] [Google Scholar]
  3. Bénard J., Da Silva J., De Blois M. C., Boyer P., Duvillard P., Chiric E., Riou G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 1985 Oct;45(10):4970–4979. [PubMed] [Google Scholar]
  4. Ferrini S., Biassoni R., Moretta A., Bruzzone M., Nicolin A., Moretta L. Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells. Int J Cancer. 1985 Sep 15;36(3):337–343. [PubMed] [Google Scholar]
  5. Ferrini S., Prigione I., Mammoliti S., Colnaghi M. I., Ménard S., Moretta A., Moretta L. Re-targeting of human lymphocytes expressing the T-cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies. Int J Cancer. 1989 Aug 15;44(2):245–250. doi: 10.1002/ijc.2910440210. [DOI] [PubMed] [Google Scholar]
  6. Finke J. H., Rayman P., Alexander J., Edinger M., Tubbs R. R., Connelly R., Pontes E., Bukowski R. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res. 1990 Apr 15;50(8):2363–2370. [PubMed] [Google Scholar]
  7. Hendriks R. W., Thompson A., Kraakman M. E., Drayer A. L., Schuurman R. K. Antisera to human IgE can also recognize IgA and IgM molecules as produced by selected B lymphoblastoid cell lines. Clin Exp Immunol. 1988 Nov;74(2):305–310. [PMC free article] [PubMed] [Google Scholar]
  8. Heo D. S., Whiteside T. L., Johnson J. T., Chen K. N., Barnes E. L., Herberman R. B. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res. 1987 Dec 1;47(23):6353–6362. [PubMed] [Google Scholar]
  9. Hérin M., Lemoine C., Weynants P., Vessière F., Van Pel A., Knuth A., Devos R., Boon T. Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer. 1987 Mar 15;39(3):390–396. doi: 10.1002/ijc.2910390320. [DOI] [PubMed] [Google Scholar]
  10. Ioannides C. G., Freedman R. S., Platsoucas C. D., Rashed S., Kim Y. P. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol. 1991 Mar 1;146(5):1700–1707. [PubMed] [Google Scholar]
  11. Itoh K., Platsoucas C. D., Balch C. M. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med. 1988 Oct 1;168(4):1419–1441. doi: 10.1084/jem.168.4.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jung G., Honsik C. J., Reisfeld R. A., Müller-Eberhard H. J. Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4479–4483. doi: 10.1073/pnas.83.12.4479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kast W. M., Offringa R., Peters P. J., Voordouw A. C., Meloen R. H., van der Eb A. J., Melief C. J. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell. 1989 Nov 17;59(4):603–614. doi: 10.1016/0092-8674(89)90006-8. [DOI] [PubMed] [Google Scholar]
  14. Kradin R. L., Kurnick J. T., Lazarus D. S., Preffer F. I., Dubinett S. M., Pinto C. E., Gifford J., Davidson E., Grove B., Callahan R. J. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1989 Mar 18;1(8638):577–580. doi: 10.1016/s0140-6736(89)91609-7. [DOI] [PubMed] [Google Scholar]
  15. Kradin R., Dubinett S., Mullin J., Boyle L., Strauss H. W., Bourgoin P. M., Preffer F. I., Kurnick J. Treatment of patients with advanced cancer using tumor-infiltrating lymphocytes and interleukin 2. Transplant Proc. 1988 Apr;20(2):336–338. [PubMed] [Google Scholar]
  16. Kuppner M. C., Hamou M. F., de Tribolet N. Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res. 1988 Dec 1;48(23):6926–6932. [PubMed] [Google Scholar]
  17. Kurnick J. T., Kradin R. L., Blumberg R., Schneeberger E. E., Boyle L. A. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol. 1986 Mar;38(3):367–380. doi: 10.1016/0090-1229(86)90247-3. [DOI] [PubMed] [Google Scholar]
  18. Mezzanzanica D., Canevari S., Ménard S., Pupa S. M., Tagliabue E., Lanzavecchia A., Colnaghi M. I. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Int J Cancer. 1988 Apr 15;41(4):609–615. doi: 10.1002/ijc.2910410422. [DOI] [PubMed] [Google Scholar]
  19. Miescher S., Whiteside T. L., Moretta L., von Fliedner V. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol. 1987 Jun 1;138(11):4004–4011. [PubMed] [Google Scholar]
  20. Oosterwijk E., Ruiter D. J., Hoedemaeker P. J., Pauwels E. K., Jonas U., Zwartendijk J., Warnaar S. O. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986 Oct 15;38(4):489–494. doi: 10.1002/ijc.2910380406. [DOI] [PubMed] [Google Scholar]
  21. Pisani R. J., Leibson P. J., McKean D. J. In vitro activation of lymphocytes from nonsmall cell cancer patients by interleukin 2 and anti-CD3 antibody. Clin Immunol Immunopathol. 1989 Mar;50(3):348–363. doi: 10.1016/0090-1229(89)90142-6. [DOI] [PubMed] [Google Scholar]
  22. Rabinowich H., Steiner Z., Klajman A. Clonal analysis of human tumor infiltrating lymphocytes reactive with autologous tumor cells: different target cell specificities of NK-like and cytotoxic T-cell clones. Cell Immunol. 1987 Feb;104(2):210–217. doi: 10.1016/0008-8749(87)90023-2. [DOI] [PubMed] [Google Scholar]
  23. Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep 19;233(4770):1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  24. Sato T., Sato N., Takahashi S., Koshiba H., Kikuchi K. Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. Cancer Res. 1986 Sep;46(9):4384–4389. [PubMed] [Google Scholar]
  25. Schoof D. D., Jung S. E., Eberlein T. J. Human tumor-infiltrating lymphocyte (TIL) cytotoxicity facilitated by anti-T-cell receptor antibody. Int J Cancer. 1989 Aug 15;44(2):219–224. doi: 10.1002/ijc.2910440205. [DOI] [PubMed] [Google Scholar]
  26. Taswell C., MacDonald H. R., Cerottini J. C. Clonal analysis of cytolytic T lymphocyte specificity. I. Phenotypically distinct sets of clones as the cellular basis of cross-reactivity to alloantigens. J Exp Med. 1980 Jun 1;151(6):1372–1385. doi: 10.1084/jem.151.6.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Topalian S. L., Muul L. M., Solomon D., Rosenberg S. A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987 Aug 24;102(1):127–141. doi: 10.1016/s0022-1759(87)80018-2. [DOI] [PubMed] [Google Scholar]
  28. Topalian S. L., Solomon D., Rosenberg S. A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989 May 15;142(10):3714–3725. [PubMed] [Google Scholar]
  29. Van Dijk J., Tsuruo T., Segal D. M., Bolhuis R. L., Colognola R., van de Griend R. J., Fleuren G. J., Warnaar S. O. Bispecific antibodies reactive with the multidrug-resistance-related glycoprotein and CD3 induce lysis of multidrug-resistant tumor cells. Int J Cancer. 1989 Oct 15;44(4):738–743. doi: 10.1002/ijc.2910440431. [DOI] [PubMed] [Google Scholar]
  30. Van de Griend R. J., Van Krimpen B. A., Bol S. J., Thompson A., Bolhuis R. L. Rapid expansion of human cytotoxic T cell clones: growth promotion by a heat-labile serum component and by various types of feeder cells. J Immunol Methods. 1984 Feb 10;66(2):285–298. doi: 10.1016/0022-1759(84)90340-5. [DOI] [PubMed] [Google Scholar]
  31. Wang Y. L., Si L. S., Kanbour A., Herberman R. B., Whiteside T. L. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Cancer Res. 1989 Nov 1;49(21):5979–5985. [PubMed] [Google Scholar]
  32. Whiteside T. L., Miescher S., Moretta L., von Fliedner V. Cloning and proliferating precursor frequencies of tumor-infiltrating lymphocytes from human solid tumors. Transplant Proc. 1988 Apr;20(2):342–343. [PubMed] [Google Scholar]
  33. Wong J. T., Pinto C. E., Gifford J. D., Kurnick J. T., Kradin R. L. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies. J Immunol. 1989 Nov 15;143(10):3404–3411. [PubMed] [Google Scholar]
  34. van Dijk J., Warnaar S. O., van Eendenburg J. D., Thienpont M., Braakman E., Boot J. H., Fleuren G. J., Bolhuis R. L. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int J Cancer. 1989 Feb 15;43(2):344–349. doi: 10.1002/ijc.2910430230. [DOI] [PubMed] [Google Scholar]
  35. van de Griend R. J., Goedegebuure S. P., van Krimpen B. A., Bolhuis R. L. Cloning of human CD3+ T cells and CD3- natural killer cells and requirements for long-term expansion. Transplant Proc. 1988 Apr;20(2):149–154. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES